Boehringer Ingelheim announces collaboration with MabGenesis

Boehringer Ingelheim, a global leader in animal health, and MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan, announce that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments. Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against […]